



## Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

DUBLIN, April 2, 2025 /PRNewswire/ -- [Alkermes plc](#) (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "*Development of Orexin Receptor Agonist in Sleep-Wake Disorders*" at the upcoming 24<sup>th</sup> Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on [www.alkermes.com](http://www.alkermes.com) and will be archived for 14 days.

### **About Alkermes plc**

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at [www.alkermes.com](http://www.alkermes.com).

Alkermes Contact:  
Jamie Constantine  
Investor Relations  
+1 781 873 2402



View original content to download multimedia: <https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302418938.html>

SOURCE Alkermes plc